Growth-Hormone Secretagogue Peptides

A 16-amino-acid fragment of the C-terminus of human growth hormone (residues 176–191), marketed for fat-loss lipolytic activity but weak in controlled human trials.

A long-acting GHRH analog featuring a Drug Affinity Complex that covalently binds serum albumin, extending the half-life to 6–8 days and producing sustained, continuous GH and IGF-1 elevation.

The most widely used GHRH + GHRP stack — CJC-1295 extends GHRH half-life while Ipamorelin selectively amplifies GH pulses without disturbing cortisol or prolactin.

A modified GHRH (1-29) analog without the Drug Affinity Complex — produces discrete, pulsatile GH release with a ~30-minute half-life, closely mimicking endogenous GH secretion patterns.

An early-generation growth-hormone-releasing peptide with potent GHSR agonism but notable prolactin elevation compared to the later selective agent Ipamorelin.

The first-generation growth-hormone-releasing peptide, notable for inducing strong hunger through ghrelin-receptor activation alongside GH release.

A synthetic decapeptide identical to endogenous gonadotropin-releasing hormone (GnRH) — used diagnostically to assess pituitary gonadotroph reserve and therapeutically to stimulate LH/FSH release.

A synthetic analog of endogenous GnRH (gonadotropin-releasing hormone) used clinically to evaluate pituitary gonadotropin reserve and investigated for fertility and hormonal optimization protocols.

A potent GHRP with documented cardioprotective effects in ischemic animal models, distinct from other GHRPs in its non-GH receptor activity.

A modified fragment of human growth hormone (amino acids 176-191) that retains GH's lipolytic activity without its growth-promoting or diabetogenic effects. The most targeted fat-loss peptide in research use.

An oral, non-peptide growth hormone secretagogue that mimics ghrelin at the GHSR-1a receptor — produces sustained GH and IGF-1 elevation without injections. Extensively studied in human trials.

The most selective GHRP (growth-hormone-releasing peptide) — amplifies GH pulses via ghrelin/GHSR receptor without meaningful cortisol, prolactin, or aldosterone crosstalk.

The full-length 54-amino-acid product of the KISS1 gene — the master upstream regulator of the hypothalamic GnRH pulse generator, central to puberty onset, reproductive cyclicity, and fertility.

Lanreotide is an FDA-approved synthetic cyclic octapeptide somatostatin analog marketed as Somatuline Depot (US) and Somatuline Autogel (EU/UK). It binds primarily to SSTR2 and SSTR5, and is approved for acromegaly (2007) and gastroenteropancreatic neuroendocrine tumors (GEP-NETs, 2014), with the landmark CLARINET trial establishing its antiproliferative effect in NETs.

An FDA-approved oral ghrelin receptor agonist used as a diagnostic test for adult growth hormone deficiency — the first and only oral GH stimulation test approved in the United States.

Octreotide is an FDA-approved synthetic cyclic octapeptide analog of somatostatin used to treat acromegaly, carcinoid syndrome, and vasoactive intestinal peptide-secreting tumors (VIPomas). Marketed as Sandostatin (immediate-release) and Sandostatin LAR (long-acting depot), it inhibits growth hormone, glucagon, and insulin secretion by binding to somatostatin receptor subtypes 2 and 5.

Pasireotide is an FDA-approved cyclohexapeptide somatostatin analog with uniquely broad receptor binding across SSTR1, 2, 3, and 5. Marketed as Signifor (subcutaneous) and Signifor LAR (long-acting depot), it is approved for Cushing's disease (2012) and acromegaly (2014), distinguished from older somatostatin analogs by its highest affinity for the SSTR5 subtype critical in corticotroph adenomas.

The first synthetic GHRH analog approved for clinical use — GHRH (1-29) NH₂, the minimum active sequence. Shorter-acting than tesamorelin or CJC-1295.

FDA-approved synthetic GHRH analog indicated for HIV-associated lipodystrophy, studied for visceral adipose tissue reduction and cognitive endpoints.